promo_leaderboard Ad
‹ All stocks
LQDA

Liquidia

LQDA · NASDAQ · Healthcare
$56.19
▼ $0.18 (-0.32%)
$25.01 $40.57 $56.13 $71.69 $56.19 Sep 2026 Oct 2026 Nov 2026
Day range
$55.92 – $57.21
Year range
$22.31 – $93.61
Open
$56.49
Previous close
$56.37
Market cap
$5.06B
Volume (24h)
$118.1K
Volume (52w)
$6.63M
Performance
7D
▲ 9.32%
1M
▲ 64.64%
3M
▼ -25.41%
6M
▼ -9.33%
1Y
▲ 97.85%
YTD
▲ 78.95%
3Y
▲ 764.47%
5Y
▲ 1116.24%
All-time
▲ 406.22%
Key statistics
P/E ratio
-45.68
EPS (TTM)
$-1.23
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
90.1M
About Liquidia

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Visit website
Country: United States of America
Related news
More in Healthcare